Deglutition
Conditions
Keywords
Dexmedetomidine, Swallowing function, Anesthetic sedation
Brief summary
The purpose of the study is to evaluate the impact of dexmedetomidine on swallowing function in healthy volunteers using combined pressure and impedance recordings. Furthermore, two different concentrations of dexmedetomidine will be studied to find out whether any posible impact of dexmedetomidine on swallowing function is dose-dependent.
Detailed description
Monitored anesthesia care (MAC) is commonly applied in modern perioperative care and means that minor surgical procedures are accomplished in awake patients using local anesthesia and light sedation. MAC has many advantages compared to general anesthesia; the recovery time after anesthesia is shorter and risk for postoperative nausea is lower to mention some. However, the patient is spontaneously breathing and the airway is not protected by an endotracheal tube which potentially increases risk of pulmonary aspiration. Pulmonary aspiration, that is inhalation of stomach and/or pharyngeal contents into the lungs, is a severe anesthesia-related complication and can in worst case lead to pneumonia and even death. Intact swallowing function is crucial in avoiding aspiration and how sedatives and analgesic agents used during MAC influence swallowing function is not fully understood. Pharyngeal function during bolus swallowing is measured by combined high resolution impedance manometry (HRIM). The HRIM catheter is inserted through the nose in such a way that sensors straddle the entire pharynx and esophagus with the distal catheter tip in the stomach. Dynamic pressure changes and flow can be detected during swallowing and data registered by HRIM are analysed using purpose-designed software, AIM analysis (automated impedance manometry analysis). AIM analysis derives pressure flow variables which describe different physiological events like bolus timing and bolus distension in the pharynx and the esophagus during swallowing. A Swallow Risk Index value, quantifying risk of deglutitive aspiration, can also be defined. The aim of the study is to evaluate impact of dexmedetomidine on swallowing function in healthy volunteers.Dexmedetomidine is a selective alfa-agonist frequently used during MAC. Furthermore, two different concentrations of dexmedetomidine will be studied to find out whether any posible impact of dexmedetomidine on swallowing function is dose-dependent. Moreover, subjective swallowing difficulties will be assessed. 20 healthy volunteers will be studied on two different occasions approximately one week apart. In a randomized order volunteers will receive intravenous infusion of dexmedetomidine in two subsequent concentrations and placebo (normal saline) infusion in corresponding doses on the other occasion. Blood samples are obtained for plasma concentration determination of the study drug and sedation levels are assessed during study drug exposure.
Interventions
DRUGPlacebo
Placebo (NaCl 0.9%) TCI infusion
DRUGDexmedetomidine
Dexmedetomidine TCI 0.6 ng/ml and 1.2 ng/ml
Sponsors
Region Örebro County
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
1. ≥ 18 - ≤ 40 year old healthy volunteers from both sexes. 2. Have signed and dated Informed Consent. 3. Willing and able to comply with the protocol for the duration of the trial.
Exclusion criteria
1. Anamnesis of pharyngoesophageal dysfunction. 2. Known or history of gastrointestinal, severe cardiac, pulmonary or neurological disease 3. Ongoing medication that may affect upper gastrointestinal tract, larynx or lower airway. 4. Allergies to or history of reaction to remifentanil, fentanyl analogues or dexmedetomidine. 5. Known heart rhythm disorder. 6. Tendency to faint. 7. Pregnancy or breast feeding 8. BMI \> 30 9. Smoking 10. Participation in a medicinal clinical trial during the last year where an opioid has been used or have during the last 30 days participated in any other medicinal clinical trial or in a trial where follow-up is not completed.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| UES Integrated Relaxation Pressure | 60 min | Measure of UES relaxation, mmHg |
| Mean Pharyngeal Peak Pressure, dex vs baseline | 60 min | Measure of lumen occlusive pressure, mmHg |
| Mean UES Basal Pressure, dex vs baseline | 60 min | Measure of UES (upper esophageal sphincter) basal tone, mmHg |
| UES Open Time, dex vs baseline | 60 min | Measure of UES opening, sec |
| UES Maximum Admittance | 60 min | Measure of UES opening, ms |
| Swallow Risk Index, dex vs baseline | 60 minutes | Global measure of swallowing dysfunction related to aspiration risk, during swallowing between dexmedetomidine exposure and baseline compared to placebo. |
| Hypopharyngeal Intrabolus Pressure, dex vs baseline | 60 min | Measure of pharyngeal outflow resistance, mmHg |
| Mean Distension Contraction Latency, dex vs baseline | 60 min | Measure of flow timing, sec |
| Hypopharyngeal Bolus Presence Time, dex vs baseline | 60 min | Measure of bolus arrival/oral bolus control, sec |
| Velopharyngeal to Tongue Base Pressure Integral, dex vs baseline | 60 min | Measure of lumen occlusive pressure, mmHgxsxcm |
| Hypopharyngeal Contractile Integral, dex vs baseline | 60 min | Measure of lumen occlusive pressure, mmHgxsxcm |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Esophageal pressure flow variables, dex vs baseline | 60 min | Difference in pressure flow variables during swallowing between dexmedetomidine exposure and baseline compared to placebo. |
| Esophageal pressure flow variables, dex 0.6 ng/ml vs 1.2 ng/ml | 60 min | Difference in esophageal pressure flow variables during swallowing between dexmedetomidine target concentration of 0.6 ng/ml and 1.2 ng/ml compared to placebo. |
| Subjective swallowing difficulties | 60 minutes | Difference in subjective swallowing difficulties between dexmedetomidine exposure and baseline compared to placebo. |
| Pharyngeal Pressure Flow variables, dex 0.6 ng/ml vs 1.2 ng/ml | 60 minutes | Difference in pressure flow variables during swallowing between dexmedetomidine target concentration of 0.6 ng/ml and 1.2 ng/ml compared to placebo. |
Contacts
Primary ContactJohanna Savilampi, Phd
Backup ContactPer Cajander, MD
Outcome results
None listed